Topotecan Vs. Topotecan + Etoposide Vs.Topotecan + Gemcitabine in Ovarian Cancer Therapy
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
Determination of total survival under Topotecan Monotherapy, Topotecan + Etoposide and
Topotecan + Gemcitabine in second-line therapy in patient with recurrent ovarian cancer.
Phase:
Phase 3
Details
Lead Sponsor:
North Eastern German Society of Gynaecological Oncology North Eastern Germany Society of Gynaecologic Oncology